APO RESEARCH · REPORT
Meningococcal Vaccine
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
Product & engineering
Understand the product.
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
Selected research
Industry Research
Meningococcal Vaccine Industry Research Report 2026
Market perspective
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.
Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.
Read the full market overview
In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.
Report Scope
This report quantifies the global Meningococcal Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (10K Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/10K Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Meningococcal Vaccine Market by Company
Novartis
GSK
Merck
CSL
Baxter
JN International Medical Corporation
Serum Institute of India
Bio-Med
China National Biotec Group
Hualan Bio
Walvax
Zhifei
Meningococcal Vaccine Segment by Type
Meningtits A
Polysaccharide Meningtitis AC
Meningitis ACYW
Meningococcal Vaccine Segment by Application
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
Meningococcal Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Meningococcal Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Meningococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Meningtits A
- Polysaccharide Meningtitis AC
- Meningitis ACYW
Applications
- 6 Months-15Year
- over 3 Year
- over 2 Year
- over 3 Months
Companies covered
- Novartis
- GSK
- Merck
- CSL
- Baxter
- JN International Medical Corporation
- Serum Institute of India
- Bio-Med
- China National Biotec Group
- Hualan Bio
- Walvax
- Zhifei
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Meningococcal Vaccine Market Size (2021-2032)
- 2.2.2 Global Meningococcal Vaccine Sales (2021-2032)
- 2.2.3 Global Meningococcal Vaccine Market Average Price (2021-2032)
- 2.3 Meningococcal Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Meningtits A
- 2.3.3 Polysaccharide Meningtitis AC
- 2.3.4 Meningitis ACYW
- 2.4 Meningococcal Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 6 Months-15Year
- 2.4.3 over 3 Year
- 2.4.4 over 2 Year
- 2.4.5 over 3 Months
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Meningococcal Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Meningococcal Vaccine Sales (10K Pcs) of Manufacturers (2021-2026)
- 3.3 Global Meningococcal Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Meningococcal Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Meningococcal Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Meningococcal Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Meningococcal Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Meningococcal Vaccine, Established Date
- 3.9 Global Meningococcal Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Meningococcal Vaccine Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 GSK
- 4.2.1 GSK Company Information
- 4.2.2 GSK Business Overview
- 4.2.3 GSK Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GSK Meningococcal Vaccine Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Meningococcal Vaccine Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 CSL
- 4.4.1 CSL Company Information
- 4.4.2 CSL Business Overview
- 4.4.3 CSL Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 CSL Meningococcal Vaccine Product Portfolio
- 4.4.5 CSL Recent Developments
- 4.5 Baxter
- 4.5.1 Baxter Company Information
- 4.5.2 Baxter Business Overview
- 4.5.3 Baxter Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Baxter Meningococcal Vaccine Product Portfolio
- 4.5.5 Baxter Recent Developments
- 4.6 JN International Medical Corporation
- 4.6.1 JN International Medical Corporation Company Information
- 4.6.2 JN International Medical Corporation Business Overview
- 4.6.3 JN International Medical Corporation Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 JN International Medical Corporation Meningococcal Vaccine Product Portfolio
- 4.6.5 JN International Medical Corporation Recent Developments
- 4.7 Serum Institute of India
- 4.7.1 Serum Institute of India Company Information
- 4.7.2 Serum Institute of India Business Overview
- 4.7.3 Serum Institute of India Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Serum Institute of India Meningococcal Vaccine Product Portfolio
- 4.7.5 Serum Institute of India Recent Developments
- 4.8 Bio-Med
- 4.8.1 Bio-Med Company Information
- 4.8.2 Bio-Med Business Overview
- 4.8.3 Bio-Med Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bio-Med Meningococcal Vaccine Product Portfolio
- 4.8.5 Bio-Med Recent Developments
- 4.9 China National Biotec Group
- 4.9.1 China National Biotec Group Company Information
- 4.9.2 China National Biotec Group Business Overview
- 4.9.3 China National Biotec Group Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 China National Biotec Group Meningococcal Vaccine Product Portfolio
- 4.9.5 China National Biotec Group Recent Developments
- 4.10 Hualan Bio
- 4.10.1 Hualan Bio Company Information
- 4.10.2 Hualan Bio Business Overview
- 4.10.3 Hualan Bio Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hualan Bio Meningococcal Vaccine Product Portfolio
- 4.10.5 Hualan Bio Recent Developments
- 4.11 Walvax
- 4.11.1 Walvax Company Information
- 4.11.2 Walvax Business Overview
- 4.11.3 Walvax Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Walvax Meningococcal Vaccine Product Portfolio
- 4.11.5 Walvax Recent Developments
- 4.12 Zhifei
- 4.12.1 Zhifei Company Information
- 4.12.2 Zhifei Business Overview
- 4.12.3 Zhifei Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Zhifei Meningococcal Vaccine Product Portfolio
- 4.12.5 Zhifei Recent Developments
5 Global Meningococcal Vaccine Market Scenario by Region
- 5.1 Global Meningococcal Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Meningococcal Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Meningococcal Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Meningococcal Vaccine Sales by Region: 2027-2032
- 5.3 Global Meningococcal Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Meningococcal Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Meningococcal Vaccine Revenue by Region: 2027-2032
- 5.4 North America Meningococcal Vaccine Market Facts & Figures by Country
- 5.4.1 North America Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Meningococcal Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Meningococcal Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Meningococcal Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Meningococcal Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Meningococcal Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Meningococcal Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Meningococcal Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Meningococcal Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Meningococcal Vaccine Market Facts & Figures by Country
- 5.7.1 South America Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Meningococcal Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Meningococcal Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Meningococcal Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Meningococcal Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Meningococcal Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Meningococcal Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Meningococcal Vaccine Sales by Type (2021-2032) & (10K Pcs)
- 6.1.2 Global Meningococcal Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Meningococcal Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Meningococcal Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Meningococcal Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Meningococcal Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Meningococcal Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Meningococcal Vaccine Sales by Application (2021-2032) & (10K Pcs)
- 7.1.2 Global Meningococcal Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Meningococcal Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Meningococcal Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Meningococcal Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Meningococcal Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Meningococcal Vaccine Value Chain Analysis
- 8.1.1 Meningococcal Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Meningococcal Vaccine Production Mode & Process
- 8.2 Meningococcal Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Meningococcal Vaccine Distributors
- 8.2.3 Meningococcal Vaccine Customers
9 Global Meningococcal Vaccine Analyzing Market Dynamics
- 9.1 Meningococcal Vaccine Industry Trends
- 9.2 Meningococcal Vaccine Industry Drivers
- 9.3 Meningococcal Vaccine Industry Opportunities and Challenges
- 9.4 Meningococcal Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst